Recursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience

Plus, news about 2seventy, Novo Nordisk, CASI, CalciMedica, X4, NeOnc, ANI, Alimera, Holoclara, Nxera, Future Pak, Vanda and Bayer:

Recursion Pharmaceuticals is selling $200M in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Dr. Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma – Biotech Investments

EQS-News: Rentschler Biopharma SE / Key word(s): Personnel Dr. Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma 04.12.2023 / 10:00 CET/CEST The issuer is

December 5, 2023

CureVac releases mixed interim Phase 2 data for seasonal flu vaccine

CureVac’s seasonal flu vaccine boosted antibody titers in influenza A strains but it missed the mark in influenza B in a Phase 2 trial. The

April 5, 2024

Hyloris wins painkiller approval amidst amplified anti-opioid efforts – Pharmaceutical Technology

Maxigesic is an intravenous painkiller. Credit: Inside Creative House via Shutterstock. The US Food and Drug Administration (FDA) has approved Hyloris Pharmaceuticals’ non-opioid, intravenous painkiller,

October 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.